Drug intelligence / Profile preview

PRO-206

Development stage: Preclinical
Lead developer: Lantheus
Modality: Small Molecules
Administration: Oral

Overview

PRO-206 is an orally active small-molecule drug candidate designed to inhibit the entry of the Hepatitis C virus (HCV) into host cells. Developed by Prosetta Antiviral, the compound is intended to block the initial stage of the viral life cycle, thereby preventing the establishment of infection within hepatocytes. This mechanism of action is distinct from many standard-of-care direct-acting antivirals (DAAs) that target viral replication enzymes. PRO-206 is currently in the preclinical stage of development for the treatment of Hepatitis C infection.

Beyond the preview

Go deeper on PRO-206.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRO-206.

Explore the full profile